Phase I Study Of SY 5609, An Oral, Selective CDK7 Inhibitor, In Adult Patients With Select Advanced Solid Tumors, Including Pancreatic Cancer
The purpose of this phase I trial is to evaluate the safety and efficacy of SY-5609 in patients with advanced solid tumors, including pancreatic cancer.
Study ID: SY-5609-101
Trial Phase: Phase I
Trial Sponsor: Syros Pharmaceuticals
Therapies Used in This Trial: SY 5609